Warde Medical Laboratory

LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Immunochemistry

Collected: 11/24/2023 08:49 Received: 11/24/2023 08:49

Test Name	Result	Flag	Ref-Ranges	Units	Site
Prostate Specific Antigen, Total and Free					
Prostate Specific Antigen	3.0		<=4.0	ng/mL	WMRL

The intended use for this assay is measurement of serum PSA in conjunction with digital rectal examination as an aid in the detection of prostate cancer in men aged 50 years or older. There is also a second indication for this assay, which is serial measurement of PSA to aid in the prognosis and management of patients with prostate cancer; as such, specimens from patients under the age of 50 are not rejected by the laboratory. Interpretation of results, and use of provided reference range (established for the indication of prostate cancer detection in men 50 and older), should take intended uses into consideration.

Free PSA	0.50			ng/mL	WMRL
Percent Free PSA	17			%	WMRL

The % free PSA should be used to evaluate patients that have total PSA values between 2.0 and 10.0 ng/mL. For patients whose total PSA value falls below 2.0 ng/mL or above 10 ng/mL, the risk of prostate cancer is determined on the basis of total PSA alone and a Free PSA will not be calculated.

For total PSA levels between 4.0 and 10.0 ng/mL, a percent free PSA <25% indicates increased risk of prostate cancer; the lower the percentage, the greater the risk. For total PSA levels between 2.0 and 3.9 ng/mL, a percent free PSA <18% indicates increased risk of prostate cancer; the lower the percentage, the greater the risk. However, although the probability is low, cancer may be present even when the free PSA percentage is >25% (or >18% of the total PSA values between 2.0 and 3.9 ng/mL).

This test was performed using the Beckman Coulter method, calibrated to the original Hybritech Tandem-R assay. PSA values obtained with other assay methods or kits cannot be used interchangeably with results obtained by the Beckman Tandem-R method.

Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Reported Date: 11/24/2023 08:52 FPSA

Performing Site:
WMRL: WARDE MEDICAL LABORATORY 300 West Textile Road Ann Arbor MI 48108

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F524000000
WX0000003827
Printed D&T: 11/24/23 08:52

Ordered By: KAJAL SITWALA, MD, PhD
WX00000000002365

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1